Feds Eye Partial Pretrial Ruling In Regeneron FCA Case
The government has urged a Massachusetts federal judge to rule that Regeneron Pharmaceuticals "naturally or foreseeably" caused providers to present false claims for its macular degeneration drug Eylea, arguing that it...To view the full article, register now.
Already a subscriber? Click here to view full article